We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) Scheduling (national classification system) (166)
- Committees and advisory bodies (384)
- Safety monitoring and information (27)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
188 result(s) found, displaying 176 to 188
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 3 October 2017
-
Scheduling decisions (final)Final decisions for medicines and chemicals referred to March 2017 scheduling meetings (ACMS #20, ACCS #19 and Joint ACMS-ACCS #15) and NCEs.
-
Scheduling decisions (final)New Chemical Entity (NCE) delegate's final decision and reasons for decision for brexpiprazole
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closed: 31 May 2017
-
Scheduling decisions (final)Delegate-only final decisions to amend the Poisons Standard not referred to an expert advisory committee.
-
Corporate reportsRegulation impact statement: Codeine re-scheduling
-
Scheduling decisions (final)Q&A about changes to the scheduling of codeine.
-
Corporate reportsEconomic modelling and financial quantification of the regulatory impact of proposed changes to codeine scheduling
-
Corporate reportsThe Scheduling Policy Framework (SPF) is a key feature of the revised arrangements for scheduling of medicines and chemicals
-
Corporate reportsThis statement guides decision making to help address concerns with joint replacement prostheses.
-
Corporate reportsFind out when software is classified as an in vitro medical device and how it is regulated.
-
Corporate reportsThe use Global Medical Device Nomenclature (GMDN) codes for in vitro diagnostic medical devices supplied in Australia.
-
Corporate reportsThe NCCTG Scheduling Policy Framework outlines how medicines and chemicals are classified and regulated in Australia to support safe and consistent decision-making.